01 Mar Coave Therapeutics
Rodolphe Clerval, CEO
Paris, France
(Private)
Coave Therapeutics is tackling the main hurdle in gene therapy: delivery. The company has developed the world’s first ligand-conjugated AAVs, creating Precision Vectors that are highly tissue-specific, accurately delivered, and safer than traditional methods. This targeted approach enables a first-in-class precision suprachoroidal vectorcapsid aimed at transforming retinal vascular diseases such as neovascular AMD and diabetic macular edema. Coave is advancing its lead program, CoTx-101, toward clinical development with the aim of delivering a best-in-class, durable, and more convenient treatment that reduces the need for frequent injections. Its plug-and-play technology can be applied to any capsid/vector, regardless of administration route or target tissue, unlocking exploration of indications previously deemed unfeasible with standard gene therapy. Founded on pioneering science from the University of Nantes and supported by rigorous quantitative analysis, Coave is led by a team of gene therapy and ophthalmology experts.
